| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | 
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Total Revenue | 229.22B | 225.42B | 221.99B | 206.60B | 205.13B | 199.73B | 
| Gross Profit | 121.62B | 114.30B | 111.35B | 105.93B | 109.09B | 102.23B | 
| EBITDA | 26.32B | 25.91B | 33.25B | 28.52B | 37.76B | 31.64B | 
| Net Income | 13.47B | 14.10B | 17.03B | 17.11B | 23.43B | 18.24B | 
| Balance Sheet | ||||||
| Total Assets | 247.07B | 257.24B | 233.23B | 216.73B | 210.20B | 193.03B | 
| Cash, Cash Equivalents and Short-Term Investments | 44.51B | 43.43B | 50.43B | 44.46B | 60.92B | 44.61B | 
| Total Debt | 26.03B | 26.08B | 654.00M | 441.00M | 359.00M | 404.00M | 
| Total Liabilities | 69.54B | 75.94B | 52.15B | 49.13B | 53.82B | 54.05B | 
| Stockholders Equity | 175.82B | 179.55B | 181.08B | 167.60B | 156.38B | 138.98B | 
| Cash Flow | ||||||
| Free Cash Flow | 14.54B | 8.16B | 10.82B | -10.77B | 22.77B | 10.56B | 
| Operating Cash Flow | 21.74B | 15.29B | 15.61B | -2.51B | 25.70B | 13.95B | 
| Investing Cash Flow | -25.18B | -25.14B | -5.21B | -7.65B | -4.30B | -2.95B | 
| Financing Cash Flow | 2.55B | 2.55B | -6.97B | -7.49B | -7.30B | -3.01B | 
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth | 
|---|---|---|---|---|---|---|---|
| ― | ¥9.28B | 12.53 | ― | 3.63% | 3.38% | 88.65% | |
| ― | ¥16.16B | 15.75 | ― | 3.63% | -8.07% | -38.21% | |
| ― | ¥289.73B | 21.12 | ― | 1.82% | 4.43% | -1.39% | |
| ― | ¥31.04B | 10.51 | ― | 2.67% | 7.99% | 28.81% | |
| ― | ¥74.45B | 34.68 | ― | 2.38% | 3.80% | 6.68% | |
| ― | €131.79B | 11.59 | 8.31% | 4.07% | 0.70% | ― | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | 
Nihon Kohden Corporation is spearheading a new clinical study titled ‘Evaluation of SpO2 Accuracy in Children With Various Skin Color’. The study aims to assess the accuracy of blood oxygen level measurements in children with different skin tones, addressing a significant gap in pediatric healthcare and ensuring equitable medical care across diverse populations.
The recent clinical study update from Nihon Kohden Corporation, titled ‘Comparison Study of EzCVP and CVP,’ aims to evaluate the effectiveness of a non-invasive method for measuring central venous pressure (CVP) against the traditional invasive approach. This study is significant as it could revolutionize how heart failure, specifically congestive heart failure, is monitored, potentially improving patient outcomes and reducing procedure-related risks.
Study Overview: Nihon Kohden Corporation is conducting a pilot study titled Pilot Study for the Evaluation of EzCVP in Heart Failure Patients. The study aims to evaluate changes in non-invasive central venous pressure (CVP) in heart failure patients during their hospital stay and its relationship with readmission rates. This research is significant as it could lead to improved monitoring and management of heart failure, potentially reducing hospital readmissions.
Nihon Kohden Corporation has announced the termination of its distribution partnership with Abbott Medical Japan LLC, effective December 31, 2026, as part of its strategic business portfolio review. In response, the company is implementing two support programs: the Career Change Support Program for employees involved in the Abbott business, and the Next Career Support Program for employees seeking new career opportunities or early retirement. These initiatives are expected to result in extraordinary losses of approximately ¥2.4 billion in FY2025, but a reduction in SG&A expenses by around ¥2.3 billion in FY2026.
The most recent analyst rating on (JP:6849) stock is a Buy with a Yen1898.00 price target. To see the full list of analyst forecasts on Nihon Kohden Corporation stock, see the JP:6849 Stock Forecast page.
Nihon Kohden Corporation has announced the termination of its distribution partnership with Abbott Medical Japan LLC, effective December 31, 2026. This decision aligns with Nihon Kohden’s strategy to transform its business portfolio and focus on its own products, aiming for long-term growth in the domestic market. The transition will be phased to ensure minimal disruption to patients and medical institutions, with the impact on financial results expected to be minor.
The most recent analyst rating on (JP:6849) stock is a Buy with a Yen1898.00 price target. To see the full list of analyst forecasts on Nihon Kohden Corporation stock, see the JP:6849 Stock Forecast page.